The U.S. Food and Drug Administration (FDA) has approved revumenib, a pioneering drug for relapsed or refractory acute ...
The US Food and Drug Administration (FDA) has granted accelerated approval to Ziihera (zanidatamab-hrii), a novel therapy for ...
ONCOLife proudly presents an exclusive interview with Dr. Iris Kuss, VP and Global Development Lead Oncology at Bayer. In ...
Oncolytic viruses are a very promising class of therapeutic agents, with a broad range of types. In this exclusive interview ...
Researchers from Cambridge University Hospitals, in collaboration with the NHS Health Research Authority, have launched the ...
IMUNON’s Phase 2 OVATION 2 study shows promising results for its immunotherapy, IMNN-001, in advanced ovarian cancer. Combined with standard chemotherapy, IMNN-001 improved overall survival by 35% and ...
Don't miss this opportunity to hear their insights and get answers to your questions on how AI is shaping the future of healthcare. The general overview of your report, "AI In Pharmaceuticals Promises ...
Cytokine therapies have the potential to transform cancer treatment by enhancing the body’s immune response to fight cancer more effectively. In our interview with Caroline Loew, Ph.D., CEO of Mural ...
This novel DNA plasmid vaccine targets antigen-presenting cells and aims to induce a robust immune response. Prof. Lindy Durrant, CEO of Scancell, shared insights from the latest Phase 2 SCOPE trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback